About dasatinib dose adjustment

Dasatinib (Dasatinib) is a targeted drug mainly used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). In clinical use, dose adjustment is critical, especially when patients fail to achieve an expected hematological or cytogenetic response.

For adult patients, the recommended starting dose is generally100 mg/day. If a satisfactory response is not obtained at this dose, doctors may consider adjusting the dose to 140 mg/day to help patients obtain better results. In the setting of chronic phase CML, this dose increase may significantly improve patients' hematological parameters. In the setting of advanced CML or Ph+ ALL, a higher dose of 180 mg/day may also be an appropriate option, especially if the patient has an inadequate response to standard doses.

Dosage adjustments must be based on the patient's specific circumstances, including their tolerability, comorbidities, and response to treatment. In practice, physicians typically monitor patients' hematological parameters and side effects regularly to determine whether further dose adjustments are needed. In addition, when patients receive high-dose treatment, they should pay close attention to potential side effects, such as bleeding, infection, etc., and inform their doctors in time.

For pediatric patients, the dose adjustment of dasatinib also needs to be cautious. Although dose increases may be considered in adult patients when response is not achieved, in pediatric patients, particularly in the setting of chronic myelogenous leukemia (CML), dose adjustments are generally limited to 120 mg per day. Children have different physiological characteristics than adults, so more care is needed when making dose adjustments to avoid possible toxic effects.

For pediatric patientsPh+ALL, it is generally not recommended to increase the dose of dasatinib. In this case, dasatinib is often used in combination with chemotherapy to enhance its efficacy. Combination chemotherapy strategies can provide a more comprehensive treatment effect, but also need to be adjusted according to the patient's specific response and tolerance.